Esperion to Participate in Upcoming Investor Conferences
08 nov. 2018 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
01 nov. 2018 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
28 oct. 2018 17h10 HE
|
Esperion Therapeutics, Inc.
– Phase 3 Program Achieved Safety and Tolerability Objectives –– Bempedoic Acid Achieved Additional 18% to 31% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% to...
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
28 oct. 2018 17h00 HE
|
Esperion Therapeutics, Inc.
– Study Met Safety and Tolerability Endpoints in 52-Week Study –– Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 oct. 2018 17h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
02 août 2018 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Host Analyst and Investor Day Event on July 10
03 juil. 2018 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 03, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
12 juin 2018 16h01 HE
|
Esperion Therapeutics, Inc.
– Simultaneous Presentation of Full Data from 1st Phase 3 Study at ISA and Publication in the Journal Atherosclerosis – ANN ARBOR, Mich., June 12, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR)...
Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
30 mai 2018 09h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 30, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces the Appointment of Jay P. Shepard to Board of Directors
29 mai 2018 09h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 29, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...